Loading
IARC estimates 74,903 new cancer cases and 53,412 cancer deaths in Myanmar in 2024; the commonest new cancers are trachea, bronchus and lung, liver and intrahepatic bile ducts and breast. This page is assembled automatically from OnCo's data: 1 programme or law, and says what OnCo does not yet hold.
| Site | New cases | Rate | OnCo page |
|---|---|---|---|
| Trachea, bronchus and lung | 11,699 | 19.9 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Liver and intrahepatic bile ducts | 8,874 | 14.7 | Hepatocellular carcinoma |
| Breast | 7,885 | 24.5 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Stomach | 6,543 | 10.9 | Gastric & gastro-oesophageal junction cancer |
| Colorectum | 4,975 | 8.4 | Colorectal cancer |
| Cervix uteri | 4,905 | 15.2 | Cervical cancer |
| Lip, oral cavity | 3,689 | 6.1 | |
| Larynx | 2,974 | 5.0 | |
| Oesophagus | 2,786 | 4.8 | Oesophageal cancer |
| Leukaemia | 2,136 | 3.9 | Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia |
| Site | Deaths | Rate | OnCo page |
|---|---|---|---|
| Trachea, bronchus and lung | 10,899 | 18.6 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Liver and intrahepatic bile ducts | 8,156 | 13.5 | Hepatocellular carcinoma |
| Stomach | 5,353 | 9.0 | Gastric & gastro-oesophageal junction cancer |
| Breast | 3,659 | 11.4 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Cervix uteri | 3,032 | 9.4 | Cervical cancer |
| Oesophagus | 2,619 | 4.6 | Oesophageal cancer |
| Colorectum | 2,602 | 4.4 | Colorectal cancer |
| Lip, oral cavity | 2,313 | 3.9 | |
| Larynx | 1,921 | 3.2 | |
| Leukaemia | 1,495 | 2.7 | Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia |
No trial record in OnCo lists a site in Myanmar. OnCo reads sites from ClinicalTrials.gov; studies registered only elsewhere are searchable through the WHO International Clinical Trials Registry Platform.
OnCo holds no institution, company or person in Myanmar.
OnCo records approvals for United States, European Union, United Kingdom, Japan, China, Australia and India. Myanmar is not one of them, so no approval in OnCo speaks for it. See the approvals by region matrix for what is held.
A deep dive for Myanmar is ranked 25 of 60 in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.